Mean Reduction in Pain Score in Patients of Plantar Fasciitis after Triamcinolone Injection in Comparison to Autologous Blood Injection
Background: To compare mean reduction in pain score in patients of plantar fascitis treated with triamcinolone injection in comparison to autologous blood injection.
Methods: This randomized controlled trail included 100 patients with plantar fasciitis. Base line visual analogue score (VAS) was calculated for each patients. 50 patients received triamcinolone injection and 50 patients’ received ABI. VAS was calculated 6 weeks after treatment. The mean reduction in VAS in both groups was compared (p-value < 0.05 was taken as significant).
Results: The mean base line pain on VAS score of the patients in triamcinolone group 7.63 + 1.24 and in autologous blood injection group was 7.19 + 1.78. Statistically, there was no significant difference between the two groups. (p-value > 0.05). The mean of VAS score of the patients after treatment was in triamcinolone group was 2.74 + 1.34and in autologous blood injection group was 4.28 + 2.08. Statistically, there was significant difference between the two groups. (p-value < 0.05). The mean of reduction in VAS score of the patients after treatment was in triamcinolone group was 3.22 + 1.79 and in autologous blood injection group was 1.93 + 2.34. Statistically, there was no significant difference between the two groups. (p-value > 0.05).
Conclusion: Both triamcinolone injection and autologus blood injection can reduce the pain score significantly among patients with plantar fascitis. However, more reduction in pain score was seen in patients of plantar fasciitis treated with Triamcinolone injection as compared to autologous blood injection.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.